GMAB (GMAB) Stock Price & Analysis
GMAB (GMAB) fell 1.03% to USD 28.87 as of July 25, 2026 at 03:51 UTC, according to Nexqual real-time market data.
GMAB last closed at USD 29.17; the session ranged USD 28.57–29.11 on volume of 1,673,362 shares. Market capitalization is $17.72B, with a 52-week range of USD 21–35.43 (NMS). Source: Nexqual, July 25, 2026 at 03:51 UTC.
Key Statistics (as of July 25, 2026 at 03:51 UTC)
| Price | USD 28.87 |
|---|---|
| Change | ▼ 1.03% (down) |
| Previous Close | USD 29.17 |
| Open | USD 29.04 |
| Day Range | USD 28.57 – 29.11 |
| 52-Week Range | USD 21 – 35.43 |
| Volume | 1,673,362 shares |
| Market Cap | $17.72B |
| Exchange | NMS |
Technical Analysis (GMAB)
Nexqual's technical model rates GMAB "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.7 (neutral) |
| vs SMA50 | Above (USD 26.8) |
| MACD | 0.63 (positive) |
Analyst Ratings (GMAB)
Wall Street analysts rate GMAB "Strong Buy" based on 10 analysts, with a mean price target of USD 37.96 (range USD 32–43), per Nexqual as of July 25, 2026 at 03:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 37.96 |
| High Target | USD 43 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (GMAB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $7.23B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.13 vs est 0.19 ▼ miss |
| 2025-12-31 | USD 0.21 vs est 0.37 ▼ miss |
| 2025-09-30 | USD 0.65 vs est 0.45 ▲ beat |
| 2025-06-30 | USD 0.54 vs est 0.34 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financials & Fundamentals (GMAB)
| Total Revenue | $3.90B |
|---|---|
| Revenue Growth (YoY) | +25.30% |
| Gross Margin | +93.31% |
| Operating Margin | +25.11% |
| Profit Margin | +21.05% |
| ROE | +14.96% |
| Debt / Equity | 94.18 |
| Current Ratio | 2.18 |
| Total Cash | $1.52B |
| Total Debt | $5.35B |
| Free Cash Flow | $830.37M |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financial Health Score (GMAB)
Nexqual rates GMAB's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:51 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 25% |
| Balance Sheet | Mixed — $1.52B cash vs $5.35B debt |
| Cash Flow | Mixed — FCF $830M, slim 3.5% margin |
| Efficiency | Mixed — ROE 15%, ROA 8.5% |
Ownership (GMAB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +13.57% |
| Shares Outstanding | 613.94M |
| Float | 606.43M |
| Short % of Float | +1.37% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Leadership (GMAB)
GMAB is led by Jan G.J. van de Winkel (age 64), Co-Founder, President & CEO, per Nexqual as of July 25, 2026 at 03:51 UTC.
| Co-Founder, President & CEO | Jan G.J. van de Winkel (age 64) |
|---|---|
| Executive VP & CFO | Anthony Pagano (age 47) |
| Executive VP & Chief Strategy Officer | Martine J. van Vugt (age 54) |
| Senior Director, Head of Development Business Partnership & Strategy and Director | Martin Schultz (age 50) |
| VP, Head of Antibody Research Materials & Director | Mijke Zachariasse (age 52) |
Major Backers & Investors (GMAB)
Notable institutional backers of GMAB include Orbis Allan Gray Ltd, Alliancebernstein L.P., Paradigm Biocapital Advisors LP, according to Nexqual as of July 25, 2026 at 03:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbis Allan Gray Ltd | 2.07% |
| Alliancebernstein L.P. | 1.53% |
| Paradigm Biocapital Advisors LP | 1.28% |
| Arrowstreet Capital, Limited Partnership | 0.8% |
| Renaissance Technologies | 0.71% |
| Deep Track Capital, Lp | 0.59% |
| Harding Loevner LP | 0.52% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 0.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.29% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 918.22 | ▲ 7.81% |
| LEGN | Legend Biotech Corporation | USD 22.22 | ▼ 5.57% |
| DNLI | Denali Therapeutics Inc. | USD 23.11 | ▼ 2.24% |
| LKFT | Lakefront Biotherapeutics | USD 27.84 | ▼ 3.27% |
| ZLAB | Zai Lab Limited | USD 19.22 | ▼ 6.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:51 UTC. This page is informational and not investment advice.